Safety and Tolerability of Metronidazole Gel 1.3%

Insud Pharma

Status and phase

Completed

Phase 4

Conditions

Vaginosis, Bacterial

Treatments

Drug: Metronidazole Gel

Study type

Interventional

Funder types

Industry

Identifiers

NCT02392026

MG1401

Details and patient eligibility

About

Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to <18 years for the treatment of bacterial vaginosis.

Full description

A multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel 1.3% when administered as a single dose in adolescent females (aged 12 to <18 years) for the treatment of bacterial vaginosis.

Enrollment

60 patients

Sex

Female

Ages

12 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provide written assent and parent/legal guardian informed consent and authorization to disclose protected health information.
Post-menarcheal, adolescent female, 12 to <18 years of age at time of Screening/Baseline Visit (Day 1).
In good general health at Screening visit with no known medical conditions that, in the Investigator's opinion, may interfere with study participation.
Has negative urine pregnancy test result prior to study treatment initiation.
Has clinical diagnosis of bacterial vaginosis.
Agree to abstain from sexual intravaginal intercourse for study duration.
Willing to avoid alcohol ingestion for 24 hours after administration of test article.
Agree to refrain from use of intravaginal products for duration of study (e.g. lubricated condoms, tampons, diaphragms, spermicides, feminine deodorant sprays, douches). Intravaginal Uterine Device (IUD) use is acceptable as long as it has been in place for 30 days prior to study enrollment.
Willing and able to participate in study, make required visits to the study center, and comply with all study requirements including concomitant medication and other treatment restrictions.

Exclusion criteria

Pregnant, lactating, or planning to become pregnant during study period.
Currently menstruating or anticipate onset of menses during first 9 days of the study.
Experience a clinically important medical event with 90 days of Screening/Baseline Visit (Day 1).
Evidence of other infectious causes of vulvovaginal infection or condition that in the Investigator's opinion would confound the interpretation of the study results.
Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal area.
Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies (non-intravaginal) are acceptable.
Has taken disulfiram or systemic corticosteroids (oral or injected) within 14 days of Screening/Baseline Visit (Day 1).
Had sexual intravaginal intercourse within 24 hours of Screening/Baseline (Day 1).
Demonstrated previous hypersensitivity to metronidazole, either orally or topically administered, or any form of parabens or benzyl alcohol.
Known primary or secondary immunodeficiency condition/syndrome.
Being treated or planning to be treated during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma.
Using anticoagulation therapy with Coumadin (warfarin).
Previously treated with test article under this protocol.
Participate in an experimental drug/device trial within the last 30 days before Screening/Baseline Visit (Day 1).
Is judged by the Investigator to be unsuitable for any reason.